UY35584A - Composición farmacéutica, su uso y régimen de administración para contracepción programada - Google Patents

Composición farmacéutica, su uso y régimen de administración para contracepción programada

Info

Publication number
UY35584A
UY35584A UY0001035584A UY35584A UY35584A UY 35584 A UY35584 A UY 35584A UY 0001035584 A UY0001035584 A UY 0001035584A UY 35584 A UY35584 A UY 35584A UY 35584 A UY35584 A UY 35584A
Authority
UY
Uruguay
Prior art keywords
pharmaceutical composition
programmed
contraception
administration system
combination
Prior art date
Application number
UY0001035584A
Other languages
English (en)
Inventor
Dr Bernhard Lindenthal
Dr Peter Serno
Dr Ulrike Fuhrmann
Dr Ulrike Röhn
Dr Andrea Rotgeri
Dr Anne Mengel
Dr Bernd Buchmann
Dr Nico Bräuer
Dr Antonius Ter Laak
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of UY35584A publication Critical patent/UY35584A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención se relaciona con una composición farmacéutica para contracepción programada no hormonal y con procesos para preparar la esta composición farmacéutica, que comprende 2H-indazol como nuevos antagonistas del receptor EP2 en combinación con inhibidores de COX. La invención además provee un método para contracepción programada no hormonal controlada por la mujer en donde se toma una compo sición farmacéutica que comprende antagonistas de receptor EP2 en combinación con inhibidores de COX en forma programada antes de la relación sexual.
UY0001035584A 2013-05-23 2014-05-23 Composición farmacéutica, su uso y régimen de administración para contracepción programada UY35584A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13169029 2013-05-23

Publications (1)

Publication Number Publication Date
UY35584A true UY35584A (es) 2014-12-31

Family

ID=48463871

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035584A UY35584A (es) 2013-05-23 2014-05-23 Composición farmacéutica, su uso y régimen de administración para contracepción programada

Country Status (20)

Country Link
US (1) US9655887B2 (es)
EP (1) EP2999469A1 (es)
JP (1) JP6370887B2 (es)
KR (1) KR20160014598A (es)
CN (1) CN105451737B (es)
AP (1) AP2015008855A0 (es)
AR (1) AR096386A1 (es)
AU (1) AU2014270596A1 (es)
BR (1) BR112015029214A2 (es)
CA (1) CA2913085A1 (es)
CL (1) CL2015003434A1 (es)
EA (1) EA201592207A1 (es)
HK (1) HK1217640A1 (es)
MA (1) MA38606A1 (es)
MX (1) MX2015016121A (es)
PH (1) PH12015502598A1 (es)
TN (1) TN2015000511A1 (es)
TW (1) TW201522325A (es)
UY (1) UY35584A (es)
WO (1) WO2014187744A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10968201B2 (en) 2018-04-17 2021-04-06 Tempest Therapeutics, Inc. Bicyclic carboxamides and methods of use thereof
CN110215447A (zh) * 2019-06-14 2019-09-10 上海市计划生育科学研究所 甲芬那酸在避孕药物中的应用及其制备的杀精避孕药物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA959008B (en) 1994-10-24 1996-09-16 Schering Ag Competitive progesterone antagonists for demand-oriented female birth control
HU227198B1 (en) 2001-11-27 2010-10-28 Richter Gedeon Nyrt Pharmaceutical composition for emergency contraception containing levonorgestrel
US20040058975A1 (en) * 2002-06-26 2004-03-25 Schering Ag Method for fertility control
DE602006018883D1 (de) 2005-03-31 2011-01-27 Auckland Uniservices Ltd Tricylische 1,2,4-triazinoxide und zusammensetzungen davon zur therapeutischen anwendung bei krebsbehandlungen
DE102005050729A1 (de) 2005-10-19 2007-04-26 Schering Ag Verfahren zur präventiven bedarfsweisen hormonalen Kontrazeption
US20100048660A1 (en) 2006-02-10 2010-02-25 Graham Michael Wynne Treatment of duchenne muscular dystrophy
CA2671543A1 (en) 2006-12-05 2008-06-12 Chung-Ming Sun Indazole compounds
EP2222665A1 (en) * 2007-11-15 2010-09-01 Pfizer Limited Azetidines as ep2 antagonists
EP2419109B1 (en) 2009-04-14 2016-04-13 Laboratoire HRA-Pharma Method for on-demand contraception using levonorgestrel or norgestrel
NZ615430A (en) 2009-04-14 2014-06-27 Laboratoire Hra-Pharma Method for on-demand contraception
CN102459166B (zh) 2009-04-22 2015-03-25 詹森药业有限公司 作为单酰甘油脂肪酶抑制剂的氮杂环丁烷基二酰胺
AU2010265180B2 (en) 2009-06-23 2014-09-11 Bayer Intellectual Property Gmbh Pharmaceutical composition for emergency contraception
DE102009049662A1 (de) 2009-10-13 2011-04-14 Bayer Schering Pharma Aktiengesellschaft 2,5-Disubstituierte 2H-Indazole als EP2-Rezeptor-Antagonisten
US8426392B2 (en) 2009-12-09 2013-04-23 Laboratoire Hra-Pharma Method for providing emergency contraception
US20130045959A1 (en) 2010-02-01 2013-02-21 Andre Ulmann Method for late post coital contraception using ulipristal acetate
TW201326154A (zh) * 2011-11-28 2013-07-01 拜耳知識產權公司 作為ｅｐ２受體拮抗劑之新穎２ｈ－吲唑

Also Published As

Publication number Publication date
WO2014187744A1 (de) 2014-11-27
CA2913085A1 (en) 2014-11-27
BR112015029214A2 (pt) 2017-07-25
US9655887B2 (en) 2017-05-23
KR20160014598A (ko) 2016-02-11
CN105451737A (zh) 2016-03-30
CN105451737B (zh) 2018-04-10
AU2014270596A1 (en) 2015-12-03
MA38606A1 (fr) 2017-03-31
TW201522325A (zh) 2015-06-16
HK1217640A1 (zh) 2017-01-20
MX2015016121A (es) 2016-03-31
TN2015000511A1 (en) 2017-04-06
US20160089364A1 (en) 2016-03-31
PH12015502598A1 (en) 2016-02-29
EA201592207A1 (ru) 2016-06-30
AR096386A1 (es) 2015-12-30
AP2015008855A0 (en) 2015-11-30
CL2015003434A1 (es) 2016-07-22
JP6370887B2 (ja) 2018-08-08
JP2016518456A (ja) 2016-06-23
EP2999469A1 (de) 2016-03-30

Similar Documents

Publication Publication Date Title
CL2016002679A1 (es) Métodos para mejorar o acelerar la recuperación física después la cirugía por fractura de cadera.
SV2018005610A (es) Derivados de oxopiridina sustituidos
UY36452A (es) Novedosos compuestos moduladores de fxr (nr1h4)
CL2014000802A1 (es) Proceso para la preparacion de estetrol, util para terapia de reemplazo hormonal y la anticoncepcion.
BR112018068126A2 (pt) sistemas e métodos para a produção e liberação de pasta fluida gelada medicinal
ECSP16059106A (es) Composiciones de liberación retardada de linaclotida
CO2017002160A2 (es) Derivados de pirimidina sustituidos con heterociclilo opcionalmente condensados útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias
ES2973858T3 (es) Métodos para tratar infecciones cutáneas mediante la administración de un antagonista de IL-4R
AR095639A1 (es) Método y sistema para transferir configuraciones de un usuario a otro dispositivo receptor del usuario con el uso de un dispositivo móvil del usuario
BR112016013485A2 (pt) Método para preparar um produto lácteo tendo teor estável de galacto-oligossacarídeo(s)
ECSP16012582A (es) Compuestos heterocíclicos y métodos de uso
CR20170146A (es) Formas cristalinas de 5-cloro-n4-[-2-(dimetilfosforil)fenil]-n2-{2-metoxi-4-[4-(4-metilpiperazin-1-yl)piperidin-1-il]pirimidina-2,4-diamina
UY35636A (es) Formulación líquida estable
HRP20181794T1 (hr) Cervikalni pesar koji sadrži progesteron za produljeno, neprekidno i kontinuirano oslobađanje, koji se koristi za spriječavanje prijevremenog porođaja
BR112015026827A2 (pt) Formas polimórficas de cloridrato de nilotinibe
CL2017000664A1 (es) Micropartículas inyectables para la liberación hiper-localizada de agentes terapéuticos
CL2017001701A1 (es) Métodos para utilizar oligonucleótidos antisentido para smad7
IL242748B (en) Nmdar agonists for use in the treatment of autoimmune-induced glutamatergic receptor dysfunction
UY35584A (es) Composición farmacéutica, su uso y régimen de administración para contracepción programada
AR095638A1 (es) Método y sistema para transferir configuraciones de un usuario a otro dispositivo receptor del usuario
UY36474A (es) Método para producir liposomas que contienen un ingrediente farmacéutico activo
CR20150530A (es) Derivados de espiroindolina como antagonistas del receptor de la hormona liberadora de gonadotropina
DOP2015000290A (es) Benzoxazoles sustituidos
MX2017012449A (es) Tratamiento del dolor.
BR112015030593A2 (pt) dispositivo para tratamento de um tecido com ar e método para tratamento de um tecido com ar

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20211206